New Variants Involved in Taybi-Linder Syndrome

• Conditions: Taybi Linder Syndrome; Genetic Syndrome
• Interventions: Genetic: Deoxyribonucleic acid analysis

• Registration Number: NCT03222947
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Taybi-Linder syndrome (TALS, OMIM 210710) is a rare autosomal recessive disorder belonging to the group of microcephalic osteodysplastic primordial dwarfisms (MOPD). This syndrome is characterized by short stature, skeletal anomalies, severe microcephaly with brain malformations and facial dysmorphism, and is caused by mutations in RNU4ATAC. Although RNU4ATAC-associated TALS is a recognizable phenotype, an atypical presentation is sometimes observed, thus expanding the clinical spectrum (TALS-like phenotype).

This study aims to identify new variants involved in Taybi-Linder syndrome and associated phenotypes (i.e.TALS-like).

This non interventional study will be performed on patients with no proven mutation of RNU4ATAC and their blood relatives (19 samples total) by high throughput sequencing and genetic analysis of already collected deoxyribonucleic acid samples.

Altogether, such a study will allow a better understanding of the molecular mechanisms responsible for the Taybi-Linder syndrome and Taybi-Linder syndrome-like phenotypes as well as the pathophysiology of these devastating forms of microcephalic dwarfism.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-07
• Study First Submitted: 2017-07-18
• Study First Submitted QC: 2017-07-18
• Last Update Submitted: 2017-07-18
• Study First Posted: 2017-07-19
• Last Update Posted: 2017-07-19
• Study Start: 2017-09
• Primary Completion: 2018-05
• Study Completion: 2018-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• foetus or young children diagnosed with a Taybi-Linder or Taybi-Linder like syndrome, with no RNU4ATAC mutation (index case)
• aged 20 weeks pregnant to 18 years old
• parents or sibling of the index cases, with informed consent for the analysis of both their DNA sample and the one of the index case.

Read More

Exclusion Criteria

• no informed consent for the use of genetic samples for medical research

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Taybi-Linder index cases	Deoxyribonucleic acid analysis	Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
Blood relatives of Taybi-Linder index cases	Deoxyribonucleic acid analysis	Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.

Primary Outcome Measures

Name	Time	Method
Identification of new variants involved in the Taybi-Linder syndrome	Collection at time of diagnosis = less than one day	A genetic high throughput exome capture sequencing of 19 deoxyribonucleic acid samples from patients diagnosed with a Taybi-Linder like syndrome and their blood relatives

Trial Locations

Locations (1)

Service de Génétique Clinique, Groupement Hospitalier Est, Hospices Civils de Lyon; 🇫🇷 Lyon, France